Quest Diagnostics Inc. (DGX) is a leading global provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company operates primarily in the United States but has continued to expand globally through strategic acquisitions and partnerships. With its headquarters located in Secaucus, New Jersey, Quest Diagnostics is listed on the New York Stock Exchange under the symbol 'DGX'.
Established in 1967, the company has a rich history of innovation, quality and customer care. With an extensive network of testing facilities and a diversified service portfolio, the company has managed to build a reputation as an industry leader. Quest Diagnostics offers services that range from routine blood tests, such as total cholesterol, pap testing and white blood cell count, to complex, gene-based and molecular testing. They also offer a wide variety of tests that are used in the detection, diagnosis and treatment of cancer, heart disease, infectious disease, neurological disorders and other conditions.
In addition to testing services, Quest Diagnostics provides interpretive consultation through the largest medical and scientific staff in the industry. More than half a million people from hospitals, clinics, doctors' offices, employers, and patients at home utilize Quest Diagnostics’ services daily because they know they can count on reliable, fast, and accurate results.
What sets Quest Diagnostics apart is its commitment to advancing healthcare and bettering patient experiences through data-driven insights and analytics. Through its Health Trends studies and the Quest Diagnostics Health & Wellness division, the company seeks to empower better health and wellness strategies and inspire policies based on substantial and reliable healthcare data. These studies provide insights on a wide variety of health issues, including deadly diseases such as cancer and diabetes, helping the healthcare community make informed prevention and treatment plans.
Looking toward the future, Quest Diagnostics aims to remain at the forefront of the diagnostic testing industry by continuing to expand its scale and scope while maintaining a commitment to upholding the highest standards of quality and service. Its continuous strive for innovation, paired with its trusted brand in the healthcare sector, lends it a competitive edge in the growing global diagnostics market.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Shares of Quest Diagnostics Inc. rose 2.97% to $252.92 on Thursday, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average both experienced declines. This marked the stock's second consecutive day of gains despite a challenging trading session overall.
NeoGenomics reported strong Q3 2026 results with 13% year-over-year clinical revenue growth and 29% NGS revenue growth, leading to increased full-year revenue and adjusted EBITDA guidance. CEO Tony Zook announced his transition to Executive Chair, with Warren Stone becoming CEO in January 2027. The company is focused on expanding NGS and MRD offerings, achieving MolDX coverage for RaDaR immunotherapy treatment response monitoring, and investing in "Lab of the Future" initiatives.
Labcorp (NYSE: LH) shares surged to a 52-week high after the company reported strong third-quarter earnings, exceeding analyst expectations for both adjusted earnings and sales. The company raised its fiscal 2026 outlook, driven by healthy organic growth, operating efficiencies, and strategic acquisitions. Despite anticipating a $125 million impact from PAMA reimbursement headwinds in 2027, Labcorp remains positive about its future growth, banking on business momentum, its biopharma segment, and "LaunchPad initiatives."
Shares of Quest Diagnostics Inc. (DGX) rose 1.26% to $245.62, outperforming the broader market on a strong trading day where the S&P 500 Index and Dow Jones Industrial Average also saw gains. The company's stock closed 1.29% below its 52-week high of $248.84, reached on September 21st.